4D Molecular Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTREND4D Molecular Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is weak (RS Rating: 44), showing significant lag compared to the market leaders. Earnings contraction of 17% provides fundamental context to the price action. Investors should exercise caution due to high volatility (92% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.19 | +13.36% | ABOVE |
| 50 SMA | $9.44 | +10.37% | ABOVE |
| 100 SMA | $9.31 | +11.93% | ABOVE |
| 150 SMA | $9.28 | +12.23% | ABOVE |
| 200 SMA | $9.26 | +12.56% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FDMT in an uptrend right now?
FDMT has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, FDMT is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is FDMT overbought or oversold?
FDMT's RSI (14) is 54. The stock is in neutral territory, neither overbought nor oversold.
Is FDMT outperforming the market?
FDMT has a Relative Strength (RS) Rating of 44 out of 99. FDMT is currently lagging the broader market.
Where is FDMT in its 52-week range?
FDMT is trading at $10.42, which is 84% of its 52-week high ($12.34) and 78% above its 52-week low ($3.68).
How volatile is FDMT?
FDMT has a Beta of 1.35 and 52-week volatility of 92%. It's more volatile than the S&P 500 - expect bigger swings.